ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

Tamoxfin Trial accrues 6,000, Problems with Minority accrual Remain

April 2, 1993

“Confidential and Proprietary” Document Proposes Plan for National Network

February 7, 2014

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

March 31, 2000

Kirsten Goldberg Leaves The Cancer Letter For ASCO

January 7, 2011

In Congress: Senate Bill Offers 13% Increase For NCI; house Provides 9%

October 8, 1999

In Brief: McDonnell Foundation Selects Five For $400,000 Fellowships; Alberts, Verma Picked For Awards

January 4, 1991